”Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Application(BLA) resubmission with the United States Food and Drug Administration (FDA) for its lead productcandidate Ryoncil®(remestemcel-L) in the treatment of steroid-refractory acute graft versus hostdisease, with potential approval in the second half of CY2024”
@Pledge … maybe no one watered the plant!sssh, words are cheap - reiterated no less
banter and General Discussion, page-9996
-
- There are more pages in this discussion • 1,075 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |